Therapix Biosciences Ltd. (NASDAQ: TRPX) Starts Presentation at the 2017 Marcum Microcap Conference
Therapix Biosciences (NASDAQ: TRPX) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company is currently engaged in two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): THX-TS01 targets to the treatment of Tourette's syndrome; and THX-ULD01 targets the high-value and under-served market of mild cognitive impairments. For more information, visit the company's website at www.therapixbio.com About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides to users (1) access to our…

















